Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

14.91 4.56

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.97

Max

14.84

Chiffres clés
By Trading Economics
Revenu	-1.4M -14M
BPA	-0.15
Employés	37
EBITDA	312K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+121.44% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-29M 1.3B
Ouverture précédente	10.35
Clôture précédente	14.91

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 juil. 2026, 23:56 UTC

Correlated Moves

Applied Materials Inc shares are lower in after-market hours, continuing a decline since Friday amid rising oil prices and geopolitical tensions impacting the semiconductor sector.

17 juil. 2026, 23:56 UTC

Automatic Data Processing shares are lower in after-market hours, declining from a session high amid rising oil prices and geopolitical tensions impacting broader market dynamics.

17 juil. 2026, 23:56 UTC

ETF Constituents

Macro News

Consumer Staples Select Sector SPDR Fund declines in after-market trading amid broader market weakness, driven by technology stock declines and rising geopolitical tensions.

17 juil. 2026, 23:56 UTC

Comcast Corp. shares are higher in after-market hours, reflecting stability near the upper end of their one-month range amid geopolitical tensions and rising oil prices.

17 juil. 2026, 23:56 UTC

The S&P 500 Index is roughly flat in after-market trading. Geopolitical tensions in the Middle East are influencing market dynamics and raising inflation concerns.

17 juil. 2026, 23:56 UTC

News

Social Media

Micron Technology shares are lower in after-market trading amid a decline in India's smartphone shipments and ongoing memory cost pressures affecting margins.

17 juil. 2026, 23:56 UTC

No specific news for Adobe Inc. Shares are trading roughly flat in after-market hours, reflecting a slight increase since Friday's close.

17 juil. 2026, 23:51 UTC

European equity indices mixed as geopolitical tensions and rising oil prices heighten inflation fears, while Eurozone inflation eases to a four-month low.

17 juil. 2026, 23:51 UTC

Asia equity markets decline sharply amid geopolitical tensions and global tech sell-off, raising concerns over inflation and economic stability.

17 juil. 2026, 23:51 UTC

U.S. equity indices remain flat amid mixed market sentiment, geopolitical tensions, and tech stock declines, while Asian markets face significant losses.

17 juil. 2026, 23:51 UTC

Global equity markets decline amid mixed U.S. economic data and escalating geopolitical tensions, with Asia seeing significant losses.

17 juil. 2026, 23:51 UTC

ECB Expected to Raise Interest Rates Amid Rising Inflation Pressures and Geopolitical Tensions on July 23, 2026.

17 juil. 2026, 23:51 UTC

ECB's Deposit Facility Rate Expected to Rise Amid Geopolitical Tensions and Inflation Concerns, Forecasted at 0.0225% for July 23, 2026

17 juil. 2026, 23:46 UTC

Cisco Systems Inc. shares are lower in after-market hours amid broader declines in the technology sector and increased market volatility linked to geopolitical tensions.

17 juil. 2026, 23:46 UTC

Check Point Software shares are higher in after-market trading, continuing a trend of three consecutive gains. No specific news was identified to explain the movement.

17 juil. 2026, 23:46 UTC

Correlated Moves

Lam Research shares traded lower in after-market hours, reflecting broader technology sector declines amid rising geopolitical tensions and concerns over inflation and interest rates.

17 juil. 2026, 23:46 UTC

ETF Constituents

iShares MSCI Brazil ETF rises in after-market hours, led by Banco do Brasil and Petrobras A, despite broader declines in global equity indices.

17 juil. 2026, 23:46 UTC

Macro News

ETF Constituents

Crude oil prices surged amid heightened geopolitical risks, boosting the Energy Select Sector SPDR Fund's performance during after-market hours.

17 juil. 2026, 23:41 UTC

China's Loan Prime Rate 5Y set to remain steady at 3.50% amid stable market sentiment ahead of July 20, 2026 release.

17 juil. 2026, 23:41 UTC

China's Loan Prime Rate Expected to Remain Unchanged at 0.03% Amid Global Interest Rate Hikes Ahead of July 20 Announcement

17 juil. 2026, 23:41 UTC

Macro News

Correlated Moves

After market hours, iShares MSCI Germany ETF trends lower amid ongoing weakness in technology stocks and rising geopolitical tensions between the U.S. and Iran.

17 juil. 2026, 23:41 UTC

Macro News

Correlated Moves

iShares MSCI South Korea ETF declines in after-hours trading amid broader market weakness and geopolitical tensions, reflecting a cumulative return of -0.39% since Friday's close.

17 juil. 2026, 23:41 UTC

Macro News

Bitcoin is trading higher as geopolitical tensions drive crude oil prices up. The cryptocurrency remains above its 20-day moving average amid rising inflation concerns.

17 juil. 2026, 23:36 UTC

News

GameStop increased its stake in eBay to nearly 10%, acquiring 3.5 million shares for about $381 million. eBay shares are gaining in after-market trading.

17 juil. 2026, 23:36 UTC

Macro News

News

ETF Constituents

Vanguard Information Technology ETF rises slightly in after-market trading, supported by gains in Microsoft, Analog Devices, Adobe, Qualcomm, and Snowflake.

17 juil. 2026, 23:36 UTC

Correlated Moves

Texas Instruments shares declined in after-market trading amid broader technology sector weakness, following four consecutive lower daily closes.

17 juil. 2026, 23:36 UTC

Correlated Moves

Synopsys Inc shares are lower in after-market trading, reflecting broader tech sector selling pressure amid profit-taking and valuation concerns ahead of earnings reports.

17 juil. 2026, 23:36 UTC

Cadence Design Systems shares are higher in after-market hours, diverging from broader tech sector weakness amid profit-taking and valuation concerns ahead of earnings.

17 juil. 2026, 23:26 UTC

ETF Constituents

Vanguard Value ETF gains in after-market trading, supported by key holdings. Despite broader market pressures, the ETF shows modest increases.

17 juil. 2026, 23:26 UTC

Costco Wholesale Corp shares are lower in after-market hours, with no specific news identified to explain the decline since Friday's close.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

121.44% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 121.44%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.